PL2953941T3 - Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania - Google Patents

Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania

Info

Publication number
PL2953941T3
PL2953941T3 PL14708987T PL14708987T PL2953941T3 PL 2953941 T3 PL2953941 T3 PL 2953941T3 PL 14708987 T PL14708987 T PL 14708987T PL 14708987 T PL14708987 T PL 14708987T PL 2953941 T3 PL2953941 T3 PL 2953941T3
Authority
PL
Poland
Prior art keywords
modulators
compositions
modifying enzymes
methyl modifying
methyl
Prior art date
Application number
PL14708987T
Other languages
English (en)
Inventor
Brian K. Albrecht
James Edmund Audia
Andrew S. Cook
Les A. Dakin
Martin Duplessis
Victor S. Gehling
Jean-Christophe Harmange
Christopher G. Nasveschuk
Rishi G. Vaswani
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2953941(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/025639 external-priority patent/WO2013120104A2/en
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of PL2953941T3 publication Critical patent/PL2953941T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL14708987T 2013-02-11 2014-02-11 Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania PL2953941T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/025639 WO2013120104A2 (en) 2012-02-10 2013-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof
EP14708987.4A EP2953941B1 (en) 2013-02-11 2014-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
PL2953941T3 true PL2953941T3 (pl) 2017-11-30

Family

ID=50239937

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14708987T PL2953941T3 (pl) 2013-02-11 2014-02-11 Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania

Country Status (16)

Country Link
EP (1) EP2953941B1 (pl)
KR (1) KR102219441B1 (pl)
CN (1) CN105102446B (pl)
CL (1) CL2015002239A1 (pl)
CR (1) CR20150457A (pl)
IL (1) IL239985B (pl)
MA (1) MA38341B1 (pl)
ME (1) ME02730B (pl)
PE (1) PE20160044A1 (pl)
PH (1) PH12015501720A1 (pl)
PL (1) PL2953941T3 (pl)
RS (1) RS56207B1 (pl)
SG (1) SG11201506077XA (pl)
SI (1) SI2953941T1 (pl)
TW (1) TWI629273B (pl)
WO (1) WO2014124418A1 (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
UY36462A (es) 2014-12-23 2016-07-29 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20180214519A1 (en) 2015-07-24 2018-08-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
WO2017023671A1 (en) 2015-08-03 2017-02-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
MX394355B (es) 2015-10-06 2025-03-24 Epizyme Inc Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
CN105669647B (zh) * 2016-02-22 2018-05-04 上海皓元生物医药科技有限公司 一种组蛋白甲基化酶ezh2抑制剂中间体的合成方法
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
ES2975263T3 (es) 2016-06-20 2024-07-04 Novartis Ag Formas cristalinas de un compuesto triazolopirimidínico
CN109843870A (zh) * 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
EP3548032A2 (en) 2016-12-02 2019-10-09 Epizyme, Inc. Combination therapy for treating cancer
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US20210161883A1 (en) 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
WO2019094552A1 (en) * 2017-11-09 2019-05-16 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
CN109879790B (zh) * 2017-12-06 2022-09-20 华东师范大学 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法
CN111757734A (zh) 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
MX2020007974A (es) 2018-01-31 2020-09-07 Mirati Therapeutics Inc Inhibidores de complejo represivo polycomb 2 (prc2).
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
JP7453916B2 (ja) 2018-03-14 2024-03-21 バイオジェン・エムエイ・インコーポレイテッド Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グリコピラノシダーゼ阻害剤
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
US12180205B2 (en) 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
ES2968733T3 (es) 2018-12-05 2024-05-13 Biogen Ma Inc Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
WO2020139339A1 (en) 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
JP7504898B2 (ja) 2019-02-04 2024-06-24 バイオジェン・エムエイ・インコーポレイテッド 二環式エーテルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
JP7663503B2 (ja) 2019-03-08 2025-04-16 バイオジェン・エムエイ・インコーポレイテッド アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
MX2022000933A (es) 2019-07-24 2022-05-06 Constellation Pharmaceuticals Inc Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer.
AR120324A1 (es) 2019-10-29 2022-02-09 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
WO2022031701A1 (en) 2020-08-03 2022-02-10 Biogen Ma Inc. Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
IL308348A (en) 2021-05-20 2024-01-01 Sironax Ltd RIP1 modulators including cyclic ureas aztidine, their preparation and uses
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023115203A1 (en) * 2021-12-20 2023-06-29 Fairhaven Pharmaceuticals Inc. Oxer1 antagonists and uses thereof
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023788B1 (ru) * 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
JP5989805B2 (ja) * 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用

Also Published As

Publication number Publication date
IL239985B (en) 2018-11-29
ME02730B (me) 2017-10-20
PE20160044A1 (es) 2016-02-11
SI2953941T1 (sl) 2017-08-31
MA38341B1 (fr) 2018-11-30
HK1218648A1 (en) 2017-03-03
CN105102446A (zh) 2015-11-25
PH12015501720B1 (en) 2015-11-09
PH12015501720A1 (en) 2015-11-09
CL2015002239A1 (es) 2016-02-05
WO2014124418A1 (en) 2014-08-14
TW201443038A (zh) 2014-11-16
EP2953941A1 (en) 2015-12-16
CN105102446B (zh) 2018-01-23
CR20150457A (es) 2015-10-20
RS56207B1 (sr) 2017-11-30
KR20150119201A (ko) 2015-10-23
TWI629273B (zh) 2018-07-11
IL239985A0 (en) 2015-09-24
SG11201506077XA (en) 2015-08-28
MA38341A1 (fr) 2018-01-31
EP2953941B1 (en) 2017-04-05
KR102219441B1 (ko) 2021-02-23

Similar Documents

Publication Publication Date Title
IL239985A0 (en) Modulators of methyl-changing enzymes, preparations and uses thereof
SMT201700340T1 (it) Modulatori di enzimi modificanti metile, composizioni e loro utilizzo
IL244081A0 (en) Preparations and methods for modulating RNA
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
EP2992097A4 (en) Compositions and methods
EP2951283A4 (en) Compositions and methods
EP3071588A4 (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP3039131A4 (en) Enzyme composition and uses thereof
EP3038634A4 (en) Novel sez6 modulators and methods of use
EP3075097A4 (en) Construction and uses of variable-input-length tweakable ciphers
EP2983681A4 (en) Therapeutic compositions and uses thereof
EP2992334A4 (en) Novel phosphatidylalkanols and compositions thereof
EP3013364A4 (en) Tuberculosis compositions and methods of using the same
EP3087056A4 (en) Glucocerebrosidase modulators and uses thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
SG11201505891VA (en) Catalyst compositions and methods of making and using same
EP2943575A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING ENZYMES
EP3004140A4 (en) Targeted enzyme compounds and uses thereof
GB201309178D0 (en) Enzyme and uses thereof
PT3066199T (pt) Snorna, composições e utilizações
EP3043780A4 (en) Novel delivery compositions and methods of using same
EP2945703A4 (en) ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
HK1229350A1 (en) Aplnr modulators and uses thereof
HK1229568A1 (en) Construction and uses of variable-input-length tweakable ciphers